Table S1 from Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate Cancer
Wei Zhang(University of Toronto), Timothy C. Thompson(The University of Texas MD Anderson Cancer Center), Bradley M. Broom(The University of Texas MD Anderson Cancer Center), Spyridon P. Basourakos(Mayo Clinic in Arizona), Ana M. Aparicio(The University of Texas MD Anderson Cancer Center), Jeri Kim(The University of Texas MD Anderson Cancer Center), Xuhong Cao(Howard Hughes Medical Institute), Nora M. Navone(The University of Texas MD Anderson Cancer Center), Dimitrios Korentzelos(University of Pittsburgh Medical Center), Patricia Troncoso(The University of Texas MD Anderson Cancer Center), Arul M. Chinnaiyan(University of Michigan), Wenhui Wu(Shanghai Pulmonary Hospital), Paul G. Corn(Cornell University), Jianxiang Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Guang Yang(Imperial College London), Sanghee Park(Hanbat National University), Likun Li(The University of Texas MD Anderson Cancer Center), Abul Kalam Azad, Bo Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Yang Luan, Christopher J. Logothetis(The University of Texas MD Anderson Cancer Center)
Cited by 0
Related Papers
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
The Molecular Taxonomy of Primary Prostate Cancer
|Cell|2015|3.3k